PROMEGA
Lead Partner
We share your passion for science. Promega is committed to excellence in technologies to assess key processes in PROTAC- and molecular glue-induced protein degradation. From assessing protein degradation in real time, to ternary complex formation and more. Our CRIPSR content covers hundreds of pre built targets. Assay live cells in kinetic mode to determine target protein degradation rates, DC50 potency values, and recovery profiles. Let’s collaborate.
NEOsphere Biotechnologies
Programme Partner
NEOsphere Biotechnologies offers a unique proteomics platform to create broad pipelines of novel degrader targets at scale and to significantly advance degrader drug discovery programs at all stages. High-throughput data-independent mass spectrometry (DIA-PASEF) combined with expert data analysis unbiasedly screens degrader libraries against ~11,000 proteins per sample with unparalleled sensitivity and data completeness and turnaround times compatible with drug discovery. Our platform characterizes all degraders (e.g., PROTACs, molecular glues, monovalent degraders, DUB inhibitors) in intact cells, identifies novel degrader targets, monitors proteome-wide selectivity, and detects molecules acting through new E3 ligases. Mechanistic validation of degrader targets, degrader-induced E3 ligase binding or degrader-induced modification is performed using interactomics or ubiquitination analysis to an unparalleled depth of 50,000 sites.
ARAGEN
Exhibition Partner
Aragen is a trusted R&D and manufacturing partner to the global life sciences industry. From concept to commercial, we transform your ideas into solutions for better health. Whether large pharma or biotech, an agrochemical or animal health company, we provide you global resources and proven capabilities at every stage of the biopharma lifecycle, in small and large molecules. Our ability to offer end-to-end solutions or support standalone programs is underpinned by an innovation mindset, enabling technologies, and a partnership approach to every engagement. Our purpose, ‘In every molecule is the possibility for better health’ motivates us to drive the success of your programs, so that we can together transform hope into health for millions of people around the world.
DEEPKINASE
Exhibition Partner
DeepKinase pioneers in proteomics for drug discovery and development, with two leading products, DoTD and DoTK. DoTD provides mass spectrometry based quantitative proteomics to assist TPD therapeutics; results are featured in numerous IND filings. DoTK offers patented tyrosine phosphoproteomics technology, vital to understand kinase activities and signaling in cancer and immune diseases. DeepKinase is a global front-runner in proteomics analysis, driving novel research, biomarker discovery, and personalized medicine in pharmaceutical industry.
PHARMARON
Exhibition Partner
At Pharmaron, we're a leading contract research organization known for our extensive laboratory services and expertise in Target Product Degradation (TPD). With advanced facilities and a dedicated team, we specialize in customized solutions for drug discovery and development. Our TPD capabilities allow for precise evaluation of drug stability and efficacy, ensuring the delivery of top-quality pharmaceuticals. With a track record of supporting over 2000 organizations globally, we've become a trusted partner in the biopharmaceutical field.
X-CHEM
Event Partner
X-Chem is the partner you need to unlock exponential possibilities in your small molecule drug discovery. Our scientists deploy DNA-encoded library (DEL) technology, medicinal chemistry, and artificial intelligence (AI) to deliver exponentially better drug discovery solutions.
X-Chem offers services, products, and solutions that can help accelerate all aspects of drug discovery, from screen to candidate.
Catalent
Event Partner
Catalent specializes in comprehensive early-phase drug development and analytical solutions.
From preclinical candidate selection to Phase-1, Catalent offers tailored solutions to help get customers’ drugs to clinic faster. Using a data-driven scientific approach, API-sparing techniques, and advanced bioavailability enhancement technologies within a global network, Catalent helps accelerate drug development.
Catalent’s ProteoSuite ℠ Oral is a comprehensive toolkit which allows the rational selection of orally developable TPD candidates and their advancement into clinical trials.